A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non–Small Cell Lung Cancer
Conclusions:
Survival benefit was dependent on type of treatment received, with significantly better mOS observed with the use of small-molecule targeted therapy against epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements, as compared with best supportive care.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Thoracic Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Electronic Medical Records (EMR) | Immunotherapy | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Palliative | Study